Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk

Heart and Vessels

Volumn 30, Issue 4, 2015, Pages 469-476

  Fujiwara, Takayuki ^a   Yoshida, Masashi ^a   Yamada, Hodaka ^a   Tsukui, Takunori ^a   Nakamura, Tomohiro ^a   Sakakura, Kenichi ^a   Wada, Hiroshi ^a   Arao, Kenshiro ^a   Katayama, Takuji ^a   Funayama, Hiroshi ^a   Sugawara, Yoshitaka ^a   Mitsuhashi, Takeshi ^a   Kakei, Masafumi ^a   Momomura, Shin ichi ^a   Ako, Junya ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

1,5 Anhydroglucitol; Coronary artery disease; Diabetes mellitus; Postprandial hyperglycemia

Indexed keywords

1,5 ANHYDROSORBITOL; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; 1,5-ANHYDROGLUCITOL; BIOLOGICAL MARKER; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLATED SERUM ALBUMIN; SERUM ALBUMIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD LEVEL; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; YOUDEN INDEX; BLOOD; CORONARY ANGIOGRAPHY; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL;

AGED; BIOMARKERS; BLOOD GLUCOSE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DEOXYGLUCOSE; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SERUM ALBUMIN;

EID: 84938421486     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-014-0502-y     Document Type: Article

References (31)

1. The DECODE study group on behalf of the Europe an Diabetes Epidemiology Group (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European diabetes epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354(9179):617–621
2. Donahue RP, Abbott RD, Reed DM, Yano K (1987) Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 36(6):689–692
3. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A (1999) Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22(6):920–924
4. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6):1214–1219
5. Kishimoto M, Yamasaki Y, Kubota M, Arai K, Morishima T, Kawamori R, Kamada T (1995) 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18(8):1156–1159
6. Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I (1992) Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1,5-anhydroglucitol. Metabolism 41(8):862–867
7. Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T (2011) Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216(2):477–483
8. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H (2009) The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 32(1):3–107
9. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetol Int 1(1):2–20
10. Harris P, Conley M, Behar V, Rosati R (1979) The prognostic significance of the degree of coronary stenosis. Am J Cardiol 43(2):343
11. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53(6):982–992
12. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW (2005) Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165(16):1910–1916
13. Dworacka M, Winiarska H (2005) The application of plasma 1,5-anhydro-d-glucitol for monitoring type 2 diabetic patients. Dis Markers 21(3):127–132
14. Dworacka M, Winiarska H, Borowska M, Abramczyk M, Bobkiewicz-Kozlowska T, Dworacki G (2007) Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ J 71(6):962–967
15. Ohira M, Endo K, Oyama T, Yamaguchi T, Ban N, Kawana H, Nagayama D, Nagumo A, Saiki A, Murano T, Watanabe H, Miyashita Y, Shirai K (2011) Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 60(1):78–85
16. Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C (2011) Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 10:19
17. Ashraf H, Boroumand MA, Amirzadegan A, Talesh SA, Davoodi G (2013) Hemoglobin A1C in non-diabetic patients: an independent predictor of coronary artery disease and its severity. Diabetes Res Clin Pract 102(3):225–232
18. Yamanouchi T, Akanuma Y, Toyota T, Kuzuya T, Kawai T, Kawazu S, Yoshioka S, Kanazawa Y, Ohta M, Baba S, Kosaka K (1991) Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 40(1):52–57
19. Goto M, Yamamoto-Honda R, Shimbo T, Goto A, Terauchi Y, Kanazawa Y, Noda M (2011) Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr J 58(1):13–17
20. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30(1):162–172
21. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545–2559
22. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457–2471
23. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2003) Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290(4):486–494
24. Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T, Echizen T, Sasaki S, Hanada H, Osanai T, Okumura K (2007) Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22(3):146–151
25. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamas G, Tognoni G, Tuomilehto J, Villamil AS, Vozar J, Califf RM (2010) Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 362(16):1463–1476
26. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369(14):1317–1326
27. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369(14):1327–1335
28. Sawada T, Shiotani H, Terashita D, Nagasawa Y, Kim SS, Koide M, Yokoyama M (2013) Comparison of effects of α-glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. Circ J 78(1):248–255
29. Watanabe K, Suzuki T, Ouchi M, Suzuki K, Ohara M, Hashimoto M, Yamashita H, Okazaki M, Ishii K, Oba K (2013) Relationship between postprandial glucose level and carotid artery stiffness in patients without diabetes or cardiovascular disease. BMC Cardiovasc Disord 13:11
30. Ouchi M, Oba K, Motoyama M, Tsunoda M, Yamashita H, Aoyama J, Saigusa T, Ishii K, Yano H, Hashimoto M, Sekimizu KI, Suzuki T, Nakano H (2013) Postprandial glycemic control conditions in relation to urinary N-acetyl-beta-d-glucosaminidase in patients with type 2 diabetes mellitus without low glomerular filtration rate. Diabetes Technol Ther 16(1):41–47
31. Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, Ishikawa Y, Nagata Y, Munekage K, Ochi T, Hirose A, Nozaki-Fujimura Y, Noguchi S, Okamoto N, Chayama K, Suganuma N, Saibara T (2013) Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS ONE 8(11):e76161